These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70. Reduced high-affinity agonist binding at the M(1) muscarinic receptor in Alzheimer's disease brain: differential sensitivity to agonists and divalent cations. Ladner CJ; Lee JM Exp Neurol; 1999 Aug; 158(2):451-8. PubMed ID: 10415152 [TBL] [Abstract][Full Text] [Related]
71. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Maelicke A; Albuquerque EX Eur J Pharmacol; 2000 Mar; 393(1-3):165-70. PubMed ID: 10771010 [TBL] [Abstract][Full Text] [Related]
72. Generation and pharmacological analysis of M2 and M4 muscarinic receptor knockout mice. Gomeza J; Zhang L; Kostenis E; Felder CC; Bymaster FP; Brodkin J; Shannon H; Xia B; Duttaroy A; Deng CX; Wess J Life Sci; 2001 Apr; 68(22-23):2457-66. PubMed ID: 11392613 [TBL] [Abstract][Full Text] [Related]
73. Inactivation of the human brain muscarinic acetylcholine receptor by oxidative damage catalyzed by a low molecular weight endogenous inhibitor from Alzheimer's brain is prevented by pyrophosphate analogs, bioflavonoids and other antioxidants. Fawcett JR; Bordayo EZ; Jackson K; Liu H; Peterson J; Svitak A; Frey WH Brain Res; 2002 Sep; 950(1-2):10-20. PubMed ID: 12231224 [TBL] [Abstract][Full Text] [Related]
74. Development of a radioligand, [(3)H]LY2119620, to probe the human M(2) and M(4) muscarinic receptor allosteric binding sites. Schober DA; Croy CH; Xiao H; Christopoulos A; Felder CC Mol Pharmacol; 2014 Jul; 86(1):116-23. PubMed ID: 24807966 [TBL] [Abstract][Full Text] [Related]
75. Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site. Lazareno S; Popham A; Birdsall NJ Mol Pharmacol; 2000 Jul; 58(1):194-207. PubMed ID: 10860942 [TBL] [Abstract][Full Text] [Related]
77. Muscarinic receptor subtype distribution in the central nervous system and relevance to aging and Alzheimer's disease. Lebois EP; Thorn C; Edgerton JR; Popiolek M; Xi S Neuropharmacology; 2018 Jul; 136(Pt C):362-373. PubMed ID: 29138080 [TBL] [Abstract][Full Text] [Related]
78. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Wess J; Eglen RM; Gautam D Nat Rev Drug Discov; 2007 Sep; 6(9):721-33. PubMed ID: 17762886 [TBL] [Abstract][Full Text] [Related]
79. SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors. Loudon JM; Bromidge SM; Brown F; Clark MS; Hatcher JP; Hawkins J; Riley GJ; Noy G; Orlek BS J Pharmacol Exp Ther; 1997 Dec; 283(3):1059-68. PubMed ID: 9399977 [TBL] [Abstract][Full Text] [Related]
80. Targeting selective activation of M(1) for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169. Tarr JC; Turlington ML; Reid PR; Utley TJ; Sheffler DJ; Cho HP; Klar R; Pancani T; Klein MT; Bridges TM; Morrison RD; Blobaum AL; Xiang Z; Daniels JS; Niswender CM; Conn PJ; Wood MR; Lindsley CW ACS Chem Neurosci; 2012 Nov; 3(11):884-95. PubMed ID: 23173069 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]